| Name | CCB02 |
| Description | CCB02 is a selective CPAP-tubulin interaction inhibitor (IC50: 689 nM) with anti-tumor activity, showing no inhibition on cell cycle- and centrosome-related kinases, nor affecting the phosphorylation status of Aurora-A, CDK2, Plk1, Plk2, and CHK1. |
| In vitro | CCB02 perturbs CPAP PN2-3-tubulin interaction with an IC50 of 0.441 μM in a PN2-3 CPAP-GST pull-down assay. In concentrations ranging from 0.1 to 15 μM over 72 hours, CCB02 inhibits the proliferation of cancer cells with extra centrosomes (IC50s: 0.86-2.9 μM). Additionally, CCB02 activates the spindle assembly checkpoint, induces PCM proteins recruitment to centrosomes, and enhances the microtubule nucleation activities of centrosomes[1]. |
| In vivo | CCB02 (30 mg/kg, p.o. daily for 24 days) exhibits a potent anti-tumor effect in nude mice with subcutaneous human lung (H1975 T790M cells) tumor xenografts, suppresses MDA-MB-231 cell migration, and induces multipolar mitosis in mouse xenografts[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 2 mg/mL (8.5 mM), Sonication is recommeded.
DMSO : 22.5 mg/mL (95.65 mM), Sonication is recommended.
|
| Keywords | MicrotubuleAssociated | Microtubule Associated | CPAP-tubulin | CCB-02 | CCB02 | CCB 02 |
| Inhibitors Related | Flubendazole | N-Phenylbenzylamine | Mebendazole | 4-Isopropoxybenzoic acid | Pregnenolone acetate | Oxfendazole | α-Cyclodextrin | Methylene Blue | Methylene Blue trihydrate | Paclitaxel | 4'-Demethylepipodophyllotoxin | Albendazole |
| Related Compound Libraries | Bioactive Compound Library | Protease Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | High-Efficiency Gene Editing Small Molecule Library |
United States
